Consequently, the number of indications was significantly higher for patients undergoing ANA as first IL-1-INH (p < 0.0001); Figure 5 represents the first-line employment of ANA and CAN for the different indications. The gene discussed is IL1B; the disease is Crouzon syndrome-acanthosis nigricans syndrome.